AMSTERDAM, May 24, 2018 /PRNewswire/ -- BioGX B.V. continues its *BD MAX™ menu expansion with the launch of sixadditional CE-Mark infectious disease tests on Becton, Dickinson and Company's BD MAX™ Sample-to-Answer platform. This brings the company's CE-Mark menu for the BD MAX™ to eleven tests, with an additional ten planned
"With the availability of eleven CE-Mark tests, BioGX B.V. continues its leadership position in developing and manufacturing tests for the BD MAX™ platform. Expect no less from us for the next generation of Sample-to-Answer open platforms," said BioGX CEO Shazi Iqbal, Ph.D.
According to BioGX's Executive Vice President and CSO, Michael Vickery, Ph.D., "BioGX is uniquely equipped to keep pace with changing clinical needs in a world of new emerging pathogens, ever increasing identification of new molecular diagnostic targets, and improved detection technology. Our platform agnostic Sample-Ready™ lyophilized reagents, lean and scalable manufacturing, talented scientific team with a decade of Sample-to-Answer product development expertise, and exceptional customer partnerships, enable us to rapidly expand menu of multiplex assays for use on virtually any platform."
The six new CE-Mark Meningitis and Antibiotic Resistance tests on BD MAX™ are:
BioGX B.V.'s CE-Mark products are marketed and sold exclusively by BioGX B.V. or its authorized distributors and are not available for sale in the United States. For additional information, please visit www.biogx.com/eu.
About BioGX B.V.BioGX B.V., based in Amsterdam, The Netherlands, is a provider of molecular diagnostics reagents across diverse clinical applications. It is a wholly owned subsidiary of BioGX, headquartered in Birmingham, AL.
About BioGXBioGX provides partner-specified formulation and manufacturing services for custom molecular reagent components. Operating in a cGMP compliant environment, BioGX has over a decade of experience in applying its proprietary platform-agnostic reagent technology across a variety of real-time PCR and Next Generation Sequencing platforms. BioGX's Sample-Ready™ technology is applied within clinical, food safety, pharma, and water quality analysis industries worldwide.
*BD MAX™ is a registered trademark of Becton, Dickinson and Company.
Contact Information:Ken Gordon, VP, Global Sales and Marketing Office: (205) 440-3970Fax: (205) 449-8055Email: firstname.lastname@example.org
Subscribe to our Free Newsletters!
Bronchopulmonary dysplasia or chronic lung disease of infancy is seen in premature and low birth ...
Ear, nose and throat are important organs and disease in one area can affect the others. ENT ...
If you want to stop breastfeeding, then here is your guide to doing it the right way. Find the ...View All